RxDoctor Payments Data

Teresita Maqueda, MD

Internal Medicine · Burbank, CANPI 1932138013

Payments from drug & device makers

$3,689in general payments, 2019–2025

Across 166 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$697
  • Amgen$500
  • Boehringer Ingelheim$428
  • Vanda Pharmaceuticals Inc.$419
  • AbbVie$362
  • Lilly USA, LLC$241
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,66899%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,689 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$19,106
Medicare patients
57
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin153$160,622
JanuviaSitagliptin Phosphate74$94,592
EliquisApixaban41$54,330
TradjentaLinagliptin38$39,077
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$27,023
OzempicSemaglutide11$13,071
JanumetSitagliptin Phos/Metformin Hcl18$10,386
LivaloPitavastatin Calcium20$8,705
Breo ElliptaFluticasone/Vilanterol12$8,228
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp36$8,006
HumalogInsulin Lispro15$6,839
Galantamine ErGalantamine Hbr44$5,164
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro36$5,092
Losartan Potassium335$4,590
Pravastatin Sodium372$4,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$428$199,699191 claims
MerckJanuvia, Janumet$29$104,97792 claims
PfizerEliquis$116$54,33041 claims
GSKTrelegy Ellipta, Breo Ellipta$153$35,25244 claims
Novo NordiskOzempic$176$13,07111 claims
Lilly USA, LLCHumalog$241$6,83915 claims
AbbVieSynthroid$362$2,58223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →